Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine-Cisplatin Plus Envafolimab as Neoadjuvant Therapy in Resectable Biliary Tract Malignancies
NCT07599995Phase 2Not yet recruiting
- Sponsor
- Sir Run-Run Shaw Hospital
- Start
- May 2026
- Primary completion
- Mar 2028
- Modality
- Nanobodies (VHH), Monoclonal Antibodies
01
Overview
A Phase 2 trial of envafolimab in biliary tract cancer (BTC), sponsored by Sir Run-Run Shaw Hospital. Planned start May 2026; status: not yet recruiting.
02
Drugs
envafolimab
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT07599995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07599995.